Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data61
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)49
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)37
Update on mGlu4 modulator patents: 2017 to present35
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)32
FAK inhibitors in cancer, a patent review – an update on progress31
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)30
The role of patent analysis in target selection30
Caspase inhibitors: a review on recently patented compounds (2016–2023)29
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)23
A patent review of MAPK inhibitors (2018 – present)23
An updated patent review of AKT inhibitors (2020 – present)23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review20
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)20
Inhibition of GTPase KRAS G12D : a review of patent literature20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)19
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
Antiprotozoal drugs: challenges and opportunities18
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202318
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)18
An updated patent review on PD-1/PD-L1 antagonists (2022-present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
A patent review of IDH1 inhibitors (2018-present)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
An updated patent review of MALT1 inhibitors (2021–present)16
Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 202516
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
A patent and literature review of CDK12 inhibitors15
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)15
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes15
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Biofilm and bacterial membrane vesicles: recent advances14
Antimalarial drugs: what’s new in the patents?14
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs13
Are patents important indicators of innovation for Chagas disease treatment?13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
Sirtuin modulators: a review of patents from 2020 to 202413
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
An updated patent review of EZH2 inhibitors (2024–present)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
The patent review of the biological activity of tropane containing compounds12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
An updated patent review of TRPA1 antagonists (2020 – present)12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)11
A patent review of DNA polymerase theta (Polθ) targeted therapies (2019–2025)11
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)11
Correction11
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)11
A patent review of selective CDK9 inhibitors in treating cancer11
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)11
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)11
Rho kinase inhibitors: a patent review (2017–2023)10
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress10
Impact of patent-granting differences between Japan and the United States on patent protection for medical methods: insights from genome editing patents10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)10
A patent review of BRD4 inhibitors (2020–present)10
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)9
Patent landscape of small molecule inhibitors of METTL3 (2020-present)9
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)9
A patent review of CXCR7 modulators (2019-present)9
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)9
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published9
Therapeutic cysteine protease inhibitors: a patent review (2018–present)8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)8
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid8
A patent perspective of antiangiogenic agents8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update8
An updated patent review of isoflavones and isocoumarins (2018–2024)8
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)8
Nurr1 modulators – a patent review (2019–present)7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
A patent review of xanthine oxidase inhibitors (2021–present)7
Recent advances in the development of STING inhibitors: an updated patent review7
Patents involving monoamine oxidase (MAO): a comprehensive update (2022–2025) on its inhibitors and applications7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
An updated patent review on monoamine oxidase (MAO) inhibitors7
Pitfalls in patenting academic CAR-T cells therapy6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
A patent review of VEGFR-2 inhibitors: an update (2022 – present)6
An updated patent review of BRD4 degraders6
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)6
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
Anticancer drugs: where are we now?6
Natural products as a source of new anticancer chemotypes6
An updated patent review of glutaminase inhibitors (2019–2022)6
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
A review of the patent literature surrounding TRPV1 modulators6
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)6
Proteasome inhibitors as anticancer agents6
Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present)6
CBL-B – An upcoming immune-oncology target5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against Acinetobacter b5
BET inhibitors: an updated patent review (2018–2021)5
Update on JNK inhibitor patents: 2015 to present5
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)5
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
A patent review of KDM4 histone demethylase inhibitors (2014-present)5
A patent review of CHK1 inhibitors (2019 – present)5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
A patent review of MLKL modulators (2023 – present)5
A patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2022-present): an update5
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections5
0.077759027481079